<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="191940">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00593840</url>
  </required_header>
  <id_info>
    <org_study_id>07-0142 / 201106342</org_study_id>
    <nct_id>NCT00593840</nct_id>
  </id_info>
  <brief_title>Phase II Trial Evaluating Elimination of Radiation Therapy</brief_title>
  <official_title>Phase II Trial Evaluating Elimination of Radiation Therapy To Pathological N0 Neck(s) With Intensity Modulated Postoperative Radiation Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if reducing or eliminating radiation treatment to
      one or both sides of the neck where there is no evidence of cancer can help spare the side
      effects of radiation treatment for head and neck cancer. In this study, we plan to reduce
      the amount of radiation treatment received to healthy tissue
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed study will prospectively test whether this method of volume reduction can be
      implemented without a change in the historical institutional locoregional control rate
      achieved with intensity modulated postoperative radiation therapy (IMPORT). Quality of life
      measurements via validated instruments will be incorporated to establish correlation of
      volume reduction with QOL.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Eliminate radiation of PN0 neck(s) and demonstrate &gt;90% control in the unirradiated neck(s)</measure>
    <time_frame>12 months of follow-up</time_frame>
    <description>Recurrence in a PN0 neck that was not treated is the critical endpoint in this study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the rates of locoregional control, disease specific survival, overall survival, and patterns of failure</measure>
    <time_frame>5 years from completion of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate impact of treatment volume on toxicity and quality of life through the use of validated PRO QOL instruments with PTV as a continuous variable.</measure>
    <time_frame>Acute toxicity = through 90 days after completion of treatment, Late = from 90 days through patient's death</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare standard treatment volume (CTV and PTV) with protocol defined treatment volume in terms of organ specific dose volume histograms</measure>
    <time_frame>Completion of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Cancer of the Larynx</condition>
  <arm_group>
    <arm_group_label>IMRT</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>CTV1 = 66 Gy in 33 fractions
CTV2 = 60 Gy in 33 fractions
CTV3 = 56 Gy in 33 fractions
CTV3 Proto = 56 Gy in 33 fractions</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>IMRT</intervention_name>
    <arm_group_label>IMRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with pathologically proven tumors of the oral cavity, oropharynx, larynx, or
             hypopharynx .

          -  Treated with surgical resection with one (or both) side(s) of the neck pathologically
             N0.

          -  Indication for radiation therapy at the primary site or neck consisting of any of the
             below characteristics:

               -  Close margin (&lt;= 0.5 cm)

               -  Positive margin

               -  Perineural invasion

               -  Lymphovascular space invasion

               -  Metastatic disease in more than one lymph node

               -  Metastatic disease in more than one lymph node group

               -  Extracapsular extension in any lymph node

               -  Constellation of factors considered to be at risk based on the
                  multi-disciplinary tumor board discussion.

          -  Age &gt;= 18.

          -  Patients must sign study specific, IRB-approved consent form.

        Exclusion Criteria:

          -  Previous head and neck cancer other than non melanoma skin cancer.

          -  Previous head and neck surgery.

          -  Female patients who are pregnant or nursing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wade Thorstad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.siteman.wustl.edu</url>
    <description>Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</description>
  </link>
  <results_reference>
    <citation>Chao KS, Low DA, Perez CA, Purdy JA. Intensity-modulated radiation therapy in head and neck cancers: The Mallinckrodt experience. Int J Cancer. 2000 Apr 20;90(2):92-103.</citation>
    <PMID>10814959</PMID>
  </results_reference>
  <results_reference>
    <citation>Chao KS, Ozyigit G, Tran BN, Cengiz M, Dempsey JF, Low DA. Patterns of failure in patients receiving definitive and postoperative IMRT for head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2003 Feb 1;55(2):312-21.</citation>
    <PMID>12527043</PMID>
  </results_reference>
  <results_reference>
    <citation>Chao KS, Majhail N, Huang CJ, Simpson JR, Perez CA, Haughey B, Spector G. Intensity-modulated radiation therapy reduces late salivary toxicity without compromising tumor control in patients with oropharyngeal carcinoma: a comparison with conventional techniques. Radiother Oncol. 2001 Dec;61(3):275-80.</citation>
    <PMID>11730997</PMID>
  </results_reference>
  <results_reference>
    <citation>Chao KS, Deasy JO, Markman J, Haynie J, Perez CA, Purdy JA, Low DA. A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results. Int J Radiat Oncol Biol Phys. 2001 Mar 15;49(4):907-16.</citation>
    <PMID>11240231</PMID>
  </results_reference>
  <results_reference>
    <citation>Ang KK, Trotti A, Brown BW, Garden AS, Foote RL, Morrison WH, Geara FB, Klotch DW, Goepfert H, Peters LJ. Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2001 Nov 1;51(3):571-8.</citation>
    <PMID>11597795</PMID>
  </results_reference>
  <results_reference>
    <citation>O'Sullivan B, Warde P, Grice B, Goh C, Payne D, Liu FF, Waldron J, Bayley A, Irish J, Gullane P, Cummings B. The benefits and pitfalls of ipsilateral radiotherapy in carcinoma of the tonsillar region. Int J Radiat Oncol Biol Phys. 2001 Oct 1;51(2):332-43. Erratum in: Int J Radiat Oncol Biol Phys 2001 Dec 1;51(5):1465.</citation>
    <PMID>11567806</PMID>
  </results_reference>
  <results_reference>
    <citation>Jackson SM, Hay JH, Flores AD, Weir L, Wong FL, Schwindt C, Baerg B. Cancer of the tonsil: the results of ipsilateral radiation treatment. Radiother Oncol. 1999 May;51(2):123-8.</citation>
    <PMID>10435802</PMID>
  </results_reference>
  <results_reference>
    <citation>Brazilian Head and Neck Cancer Study Group.. End results of a prospective trial on elective lateral neck dissection vs type III modified radical neck dissection in the management of supraglottic and transglottic carcinomas. Head Neck. 1999 Dec;21(8):694-702.</citation>
    <PMID>10562681</PMID>
  </results_reference>
  <results_reference>
    <citation>Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, Machtay M, Ensley JF, Chao KS, Schultz CJ, Lee N, Fu KK; Radiation Therapy Oncology Group 9501/Intergroup.. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004 May 6;350(19):1937-44.</citation>
    <PMID>15128893</PMID>
  </results_reference>
  <results_reference>
    <citation>Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lef√®bvre JL, Greiner RH, Giralt J, Maingon P, Rolland F, Bolla M, Cognetti F, Bourhis J, Kirkpatrick A, van Glabbeke M; European Organization for Research and Treatment of Cancer Trial 22931.. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004 May 6;350(19):1945-52.</citation>
    <PMID>15128894</PMID>
  </results_reference>
  <results_reference>
    <citation>Perez CA, Carmichael T, Devineni VR, Simpson JR, Frederickson J, Sessions D, Spector G, Fineberg B. Carcinoma of the tonsillar fossa: a nonrandomized comparison of irradiation alone or combined with surgery: long-term results. Head Neck. 1991 Jul-Aug;13(4):282-90.</citation>
    <PMID>1907952</PMID>
  </results_reference>
  <verification_date>March 2015</verification_date>
  <lastchanged_date>March 23, 2015</lastchanged_date>
  <firstreceived_date>January 2, 2008</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Laryngeal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
